| Ytd | 9.63% | |
| 1y | 59.83% |
| Open | 1.53 | Prev Close | 1.53 | Low | 1.48 | High | 1.56 | Mkt Cap | 501.01M |
| Vol | 5.77M | Avg Vol | 7.82M | EPS | -0.24 | P/E | N/A | Forward P/E | -2.85 |
| Beta | 3.77 | Short Ratio | 14.01 | Inst. Own | 27.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 1.44 | 200-d Avg | 1.55 | 1yr Est | 6.25 |
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN),
Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the p
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consens
Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology l
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy
Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion redu
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth
Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rati
Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated co
Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected
Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r
Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus
Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therap
Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritte
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positi
Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, w
OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eli
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. cont
Study supports favorable safety and tolerability profile and clinically meaningful functional and st
Ocugen (NASDAQ:OCGN) reported quarterly sales of $1.752 million which beat the analyst consensus est
Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwang
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company report
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-t
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter resu
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin
During Tuesday's session, 275 companies made new 52-week lows.
The Dow Jones closed lower by over 100 points on Friday. When insiders purchase or sell shares, it i